Dasatinib 50mg Tablet contains dasatinib 50mg, an oral prescription tyrosine kinase inhibitor (TKI) used in the treatment of certain Philadelphia chromosome-positive (Ph+) leukemias, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib inhibits abnormal BCR-ABL signaling and other kinases involved in leukemia-cell proliferation.
Sprycel® is the reference brand containing dasatinib. Dasatinib 50mg is an established tablet strength and is available in generic products in certain markets. Treatment should be prescribed and monitored by a healthcare professional experienced in leukemia management.
Dasatinib is a targeted oral anticancer medicine belonging to the BCR-ABL tyrosine kinase inhibitor class.
It is designed to inhibit abnormal kinase proteins that contribute to the development and progression of certain leukemias. Dasatinib is particularly important in Philadelphia chromosome-positive disease, where the BCR-ABL fusion protein produces abnormal kinase activity that promotes uncontrolled leukemia-cell growth.
Dasatinib is used for eligible patients with:
Pediatric indications are also approved in certain regulatory markets and depend on age, disease status and treatment regimen.
Dasatinib blocks several tyrosine kinases, most importantly BCR-ABL, which is produced by the Philadelphia chromosome abnormality found in many patients with CML and some patients with ALL.
By inhibiting BCR-ABL signaling, dasatinib interferes with pathways that promote leukemia-cell survival and proliferation.
Dasatinib also inhibits SRC-family kinases and other kinase targets, contributing to its broader targeted activity.
Chronic myeloid leukemia is a blood cancer characterized in many patients by the presence of the Philadelphia chromosome and BCR-ABL fusion gene.
Dasatinib provides targeted inhibition of BCR-ABL and is used as an important treatment option for Ph+ CML.
For newly diagnosed adult chronic-phase CML, the standard starting dose of dasatinib in the current European product information is 100mg once daily, meaning the 50mg tablet strength may be used as part of dose adjustment or according to an individualized treatment plan rather than necessarily representing the standard starting dose.
Dasatinib is also used for Philadelphia chromosome-positive acute lymphoblastic leukemia in approved treatment settings.
Ph+ ALL contains the BCR-ABL abnormality, making BCR-ABL inhibition an important component of targeted treatment.
In adult Ph+ ALL and lymphoid blast-phase CML, the recommended starting dose in the European product information is 140mg once daily, with treatment adjustments made according to clinical response and tolerability.
Sprycel® contains dasatinib and is the reference brand.
Dasatinib 50mg is therefore commonly searched alongside:
Dasatinib 50mg, Generic Dasatinib 50mg, Generic Sprycel 50mg, Sprycel 50mg, Dasatinib 50mg Tablet, Dasatinib Alternative, Sprycel Alternative, BCR-ABL Inhibitor and CML Treatment.
Authorized generic dasatinib products are available in some markets. The European Medicines Agency has authorized generic dasatinib products containing the same active substance as the reference medicine Sprycel.
Dasatinib dosage varies substantially according to:
For adults, regulatory product information lists different starting doses for chronic-phase CML versus advanced-phase CML and Ph+ ALL. Therefore, 50mg should not be assumed to be the standard dose for every patient.
Take dasatinib exactly as prescribed by the treating oncologist. Do not alter the dose, frequency or treatment schedule without medical advice.
Dasatinib can cause adverse reactions and requires specialist monitoring.
Common or clinically important adverse effects may include:
More serious complications can occur, including significant blood-count abnormalities, pleural or pulmonary complications, pulmonary arterial hypertension and other cardiovascular or bleeding-related events.
Patients should promptly report breathing difficulties, chest discomfort, unusual bleeding, severe weakness or other concerning symptoms to their healthcare provider.
Treatment with dasatinib generally requires regular clinical and laboratory monitoring.
Healthcare professionals may monitor:
Dose interruptions or reductions may be required when significant adverse reactions or abnormal blood counts occur.
Dasatinib has clinically important drug interactions.
Medicines that affect CYP3A4 can alter dasatinib exposure. Acid-reducing medicines may also affect absorption depending on the specific formulation and prescribing information.
Patients should tell their oncologist or pharmacist about all prescription medicines, over-the-counter products, vitamins and herbal supplements before starting treatment.
Dasatinib 50mg Tablet is a prescription oncology medicine supplied for patients with an appropriate leukemia diagnosis and treatment plan.
Commercial searches include Dasatinib 50mg Tablet, Dasatinib 50mg, Generic Dasatinib 50mg, Generic Sprycel 50mg, Sprycel 50mg, Buy Dasatinib 50mg, Buy Dasatinib Online, Dasatinib 50mg Price, Dasatinib Supplier, Dasatinib 50mg Capsules/Tablets, CML Medicine, BCR-ABL Inhibitor and Leukemia Treatment.
Dasatinib should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier. Availability, prescription requirements, approved indications and import regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Dasatinib is used to treat eligible patients with Philadelphia chromosome-positive CML and Ph+ ALL, depending on the disease phase and applicable regulatory indication.
The generic name is dasatinib.
Sprycel is the reference brand containing dasatinib. Authorized generic dasatinib products contain the same active pharmaceutical ingredient, although manufacturers and formulations can differ.
Dasatinib is a targeted anticancer therapy, specifically a tyrosine kinase inhibitor. It works differently from traditional cytotoxic chemotherapy by targeting specific kinase signaling pathways.
Yes. Dasatinib inhibits BCR-ABL, the abnormal kinase associated with the Philadelphia chromosome, as well as several other tyrosine kinases.
Dasatinib is primarily used for certain forms of Philadelphia chromosome-positive leukemia, including CML and Ph+ ALL.
The appropriate dose depends on the disease and treatment setting. For example, current European product information lists 100mg once daily as the adult starting dose for chronic-phase CML and 140mg once daily for advanced-phase CML or Ph+ ALL. A 50mg tablet may therefore be used for individualized dosing or dose adjustment.
Yes. Dasatinib is an established targeted therapy for Ph+ CML, although the prescribed dose depends on the disease phase and individual clinical circumstances.
Yes. Regular blood-count monitoring is important because dasatinib can cause neutropenia, anemia and thrombocytopenia.
Common adverse effects include diarrhea, nausea, headache, fatigue, rash, fluid retention and abnormalities in blood-cell counts.
Dasatinib is a prescription anticancer medicine. It should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier and used under specialist medical supervision.
Dasatinib products are available in multiple international markets, but product names, manufacturers, regulatory approvals, prescription requirements and availability differ by country.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Dasatinib is a prescription anticancer medicine requiring specialist supervision. The appropriate dose, treatment combination, monitoring schedule and duration depend on the patient’s leukemia type, disease phase, previous therapy and clinical condition. Dasatinib can cause serious adverse reactions and clinically important drug interactions. Always follow the official prescribing information for the specific product and consult a qualified oncologist before starting, stopping or changing treatment.
Last Updated: August 23, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.